Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation
Heppner KM, Kirigiti M, Secher A, Paulsen SJ, Buckingham R, Pyke C, et al
These symptoms are generally mild to moderate in severity and can be effectively managed by dose adjustment or extending the titration period (57)
The SURMOUNT-4 trial assessed the weight maintenance with tirzepatide and had also two periods: a 36-week open-label lead-in period during which all participants took tirzepatide, followed by a 52-week double-blind treatment period during which participants were randomised to either continue on tirzepatide or switch to placebo
Eligible Medicare patients pay as little as a $50 copay for FDA-approved GLP-1s, or $140/month for compounded medications
Not Drinking Enough Water Hydration is one of the most commonly overlooked areas while using GLP-1 medications